# A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

> **NCT03636347** · PHASE2 · COMPLETED · sponsor: **Mereo BioPharma** · enrollment: 99 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency
- Emphysema
- COPD

## Interventions

- **DRUG:** Placebo Oral Tablet
- **DRUG:** Alvelestat oral tablet - dose 1
- **DRUG:** Alvelestat oral tablet - dose 2

## Key facts

- **NCT ID:** NCT03636347
- **Lead sponsor:** Mereo BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-29
- **Primary completion:** 2022-03-02
- **Final completion:** 2022-03-30
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2022-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03636347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03636347, "A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03636347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*